Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.81 |
| ▸ | POLA1 | P09884 | 2/20 | 0.81 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6668773 | 0.93 | KCNH2 (0.83) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL6706716 | 0.89 | POLA1 (1.00) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL30419552 | 0.89 | KCNH2 (1.00) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL6666985 | 0.89 | KCNH2 (1.00) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL6669876 | 0.88 | KCNH2 (0.89) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL6707899 | 0.88 | KCNH2 (0.81) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL6706361 | 0.88 | POLA1 (0.94) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL6672185 | 0.88 | KCNH2 (0.91) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL6706433 | 0.88 | KCNH2 (0.87) | KCNH2POLA1F2MEN1KMT2A | |
| SCHEMBL6707912 | 0.87 | KCNH2 (0.82) | KCNH2POLA1F2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W (US) | 2004-05-27 | — | — | US | claimed |
| US-20030153561-A1 | Pyrroloquinolones as antiviral agents | VAILLANCOURT VALERIE A (US) | 2003-08-14 | — | — | US | claimed |
| EP-1299386-A1 | PYRROLOQUINOLONES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| US-6525049-B2 | Such as N-(4-chlorobenzyl)-2-(hydroxymethyl)-6-oxo-6H-pyrrolo (3,2,1-ij)quinoline-5-carboxamide for treatment of herpes | PHARMACIA & UPJOHN COMPANY | 2003-02-25 | — | — | US | claimed |
| US-20020055636-A1 | Pyrroloquinolones as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-05-09 | — | — | US | claimed |
| WO-2002002558-A1 | PYRROLOQUINOLONES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-10 | — | — | WO | claimed |
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W (US) | 2004-05-27 | — | — | US | disclosed |
| US-6683181-B2 | MIXING POLYSTYRENE-TOSYL CHLORIDE RESIN WITH C2-12ALKYNOL; REACTING WITH AMINE TO MAKE CHEMICAL INTERMEDIATE; HERPES VIRUS TREATMENT | PHARMACIA AND UPJOHN COMAPNY | 2004-01-27 | — | — | US | disclosed |
| US-20030153561-A1 | Pyrroloquinolones as antiviral agents | VAILLANCOURT VALERIE A (US) | 2003-08-14 | — | — | US | disclosed |
| EP-1299386-A1 | PYRROLOQUINOLONES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6525049-B2 | Such as N-(4-chlorobenzyl)-2-(hydroxymethyl)-6-oxo-6H-pyrrolo (3,2,1-ij)quinoline-5-carboxamide for treatment of herpes | PHARMACIA & UPJOHN COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-20020055636-A1 | Pyrroloquinolones as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-05-09 | — | — | US | disclosed |
| WO-2002002558-A1 | PYRROLOQUINOLONES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153561-A1 | Pyrroloquinolones as antiviral agents | ZC3HAV1, ZC3HAV1L, IRF3 | KCNH2 1395/4885POLA1 18/4885F2 3325/4885 |
| US-20020055636-A1 | Pyrroloquinolones as antiviral agents | ZC3HAV1, ZC3HAV1L, IRF3 | KCNH2 1395/4885POLA1 18/4885F2 3325/4885 |
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, TGFB1 | KCNH2 4238/4885POLA1 2852/4885F2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.